JUMP REPORT
NOVAVAX (NVAX)
EARNINGS RELEASE - AUGUST 10 (AMC)
EARNINGS EXPECTATIONS:
THIS QTR: EPS: -.42/share REV: 39.58/M
___________________________________________________________
LAST QTR: EPS: -.70/share ACTUAL: -.58/share (BEAT)
____________________________________________________________
NEXT QTR: EPS: 1.35/share REV: 234.3/M
____________________________________________________________
FULL YR: EPS: 7.97/share REV: 1,100/M
____________________________________________________________
BEAT/MISS RECORD: 35% OF THE TIME THEY BEAT ESTIMATES
PRIOR ‘JUMP ZONE’ MOVES (LAST 3 QTRS %) 83.4, -12.9, 7.77
EXPECTED JUMP MOVE THIS QUARTER: 15-20%
——–
*** With market volatility at extremes there is greater risk in trading these events which may not react as they would under normal market conditions. Please take extra caution before tradin
Links To Latest News and Headlines
Fate Therapeutics (FATE) reported earnings 30 days ago. What’s next for the stock? We take a look at earnings estimates for some clues.
NVAX’s COVID-flu combo shot sparks strong immunity in seniors, fueling plans for further late-stage trials.
Novavax (NasdaqGS:NVAX) recently reported initial results from its Phase 3 trial for its COVID-19-Influenza Combination and seasonal influenza vaccines, which showed immune responses comparable to existing licensed vaccines. This positive news, coupled with the FDA’s approval of Nuvaxovid for certain age groups and the subsequent $175 million milestone payment from Sanofi, likely fueled increased investor confidence. Meanwhile, broader market gains such as the S&P 500’s upward trajectory and…
Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly: VACCINE ADVISORY COMMITTEE: In an opinion article published by The Wall Street Journal, Robert F. Kennedy Jr. stated, “Vaccines have become a divisive issue in American politics, but there is one thing all parties can agree on: The U.S. faces a crisis of public trust. Whether toward health agenci
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here’s why you should take advantage.
StockJumpers analysis and trade plans are finalized and uploaded generally one house before market cloase (3PM EST) for most events unless noticed.
“I’m sorry, this content is for members only. To access this content, you must log in with your membership credentials – OR if you are not a member yet, visit our registration page here and get signed up Looking forward to having you on-board ASAP”
There is a significant amount of data behind the scenes involved in the analysis and trade plan tab above, that does not get put into the report. Too much information for traders often confuses things – so this is stripped down to only what is needed to make the best possible decision(s) on trading the trajectory.
| Avg Daily Volume: 8,831,772 Market Cap: 5.65B Sector: Healthcare Short Interest: 13.87 |
Ticker delayed 20 minutes
NOTICE: All material on this site has been published for informational and educational purposes only and does not constitute an offer to sell nor a solicitation of an offer to buy any security which may be referenced here or in our websites. StockJumpers is not an Investment Adviser and relies on the publisher’s exemption as defined in Section 401(f) of the Uniform Securities Act, and provides no personal advice or recommendations. The services and published information contained herein is for non-commercial, educational use and display. StockJumpers and any of its affiliates does not represent that the securities or services discussed are suitable for any investor. You should assume that StockJumpers and or its management has or will take a position in the stock, whether it is stated or not. You are further advised not to rely on any information contained in this report and associated websites in the process of making a fully informed investment decision. Trading is risky and you can lose your investment. For the complete risk disclosure and other legal information please review the full Terms of Use Agreement.